aromaplex 25 mg film-coated tablet film-coated tablet
genepharm s.a, greece - exemestane - film-coated tablet - 25 mg
aromaplex 25 mg film-coated tablet film-coated tablet
genepharm s.a, greece - exemestane - film-coated tablet - 25 mg
exemestane tablet, film coated
mylan pharmaceuticals inc. - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane 25 mg - exemestane tablets are indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies (14.1)] . exemestane tablets are indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies (14.2)]. exemestane tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. based on findings in animal studies and its mechanism of action, exemestane tablets can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased inc
exemestane tablet, film coated
hikma pharmaceuticals usa inc - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane 25 mg - exemestane is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies (14.1)]. exemestane is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies (14.2)]. exemestane is contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. risk summary based on findings in animal studies and its mechanism of action, exemestane can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased incidence of abortions, embryo-feta
exemestane 25mg tablets
viatris uk healthcare ltd - exemestane - oral tablet - 25mg
tamoxifen 20mg film-coated tablets tablets film-coated
cp pharmaceuticals ltd. - tamoxifen (tamoxifen citrate) - tablets film-coated - 20mg
tamoxifen 10mg film-coated tablets tablets film-coated
cp pharmaceuticals ltd. - tamoxifen (tamoxifen citrate) - tablets film-coated - 10mg
kisqali film-coated tablet 200mg
novartis (singapore) pte ltd - ribociclib succinate 254.4mg eqv ribociclib - tablet, film coated - ribociclib succinate 254.4mg eqv ribociclib 200mg
exemestan sandoz 25 mg film-coat. tabl.
sandoz sa-nv - exemestane 25 mg - film-coated tablet - 25 mg - exemestane 25 mg - exemestane
exemestane 25mg tablets
beacon pharmaceuticals ltd - exemestane - oral tablet - 25mg